TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Efficiency of FMT on T2DM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: geometric mean titer fold increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Social Perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Startle Hyperactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inter-puff-interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Puff Flow Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Puff Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug Effects/Liking Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Modified Cigarette Evaluation Questionnaire (mCEQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cigarette Purchase Task
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of patients classified as a success
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Ocular safety assessed by BCVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Standardized Uptake Value Ratio (SUVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate of central nervous system (CNS) metastasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: clinical sensitivity and specificity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Body lead burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Identification of Toddler's fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Drug-Induced Extrapyramidal Symptoms Scale (DIESS) results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Diagnostic accuracy of MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Wolf Motor Function Test (Time)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coronary Clearance Frame Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Daily Diary
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Activity levels, i.e. number of steps taken
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3 year progression free survival
Endpoint domain: Mortality/survival
Primary endpoint: Short term Variability of foetal rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aggressiveness level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: SP-B Content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in tear osmolarity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Ocular Surface Disease Index (OSDI) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: CD4+ and CD8+ T cell function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Enhanced CFTR activity impact on inflammatory cell function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: T cell subsets control of infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of chronic pain after operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of soft palate under anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of base of tongue under anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Edema (Swelling)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of proinflammatory cytokines IL-6, IL-8 and TNF-α and anti-inflammatory cytokine IL-10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Decline in HCV-RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients who complete both baseline and follow up CPET tests without significant testing-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Respiratory Compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pharmacokinetics of Ixabepilone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mean Number of Uveitis Relapses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prevalence of neurologic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence of neurologic signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Spontaneous Stone Passage (Distal Stones)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Spontaneous Stone Passage (All Stones)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: EQ-5D quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: balance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Influenza-like Illness
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Residual Ischemia (iFR <0.90)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in Blood Pressure Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement of UPDRS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of dyskinesias score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Gut-homing, activated, CD8+ αβ T cells and γδ T cells in PBMC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Evaluation of Gliadin reactive T cell measures- PBMC by Flow Cytometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Gliadin reactive T cell measures- PBMC by ELISPOT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Level of Knowledge about sexual harassment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Voice Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients experiencing moderate or greater right heart failure within 6 months post-operatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients experiencing moderate or greater right heart failure at 12 months post-operatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasmatic levels of Interleukine 6 and 1B, and Tumor Necrosis Factor alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Detection rate of thromboembolic focus/foci
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: overall prognosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vastus lateralis cross sectional area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Single fiber cross sectional area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Fat-and-bone free-mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Occurrence of new areas of infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Social role participation
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Proportion of antibiotic prescriptions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Subjects With Any Solicited Local Symptoms After First Vaccination Dose
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of weight loss ≥5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Efficacy of AD 923 in managing breakthrough pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in total Bladder Capacity after standardized treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Pain level after standardized treatment: Pelvic Pain - Urgency Frequency symptom scale
Endpoint domain: Adverse events/effects
Primary endpoint: Any new Adverse events related to treatment modalities
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of gene mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Development patterns of neuropsychological markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Complete Spontaneous Bowel Movements (CSBM) per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: AAI index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GERD Health-Related Quality of Life (HRQL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Esophageal pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Satisfactory relief of abdominal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in plasma folate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in erythrocyte folate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maternal malaria at delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Death and/or symptomatic recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Glycosylated Hemoglobin (HbA1c) at month 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Global Change in Brain Glucose Uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Global Change in Brain Ketone Uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Adolescent HIV Testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of patients correctly treated
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion Rate of 1 Year of Bevacizumab Therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Early Child Development
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Child Growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of surgical method
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Level of fatty acids in whole blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in the number of BPPV recurrences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in systolic blood pressure (SBP) AUC 0-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Variability in surface electrical potential measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: World Health Organization Quality of Life-Old module
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Elastin degradation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Ang1-7 Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Diagnostic accuracy of EMA assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of rapid anti-TG2 test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative number of new gadolinium-enhancing MRI lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Caries Progression rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in recognition of abusive behaviour
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in acceptance of myths about domestic violence
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: improvement in mask wearing behavior
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: improvement in social distancing behavior
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: improvement in hand washing behavior
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: improvement in daily fruit consumption
Endpoint domain: Life impact
Endpoint subdomain: Nutrition
Primary endpoint: improvement in the amount of daily sleep hours
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: improvement in the amount of weekly minutes of exercise
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Feasibility of chemotherapy protocols
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of participants to receive first dose
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: AUCinf of metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Clr of metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence Rate of Severe Radiation Mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Presence of rhabdomyolysis based on serum CK concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in SIGH-D-17 Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: immunity measured by inflammatory/immune biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: body metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety serological parameters
Endpoint domain: Adverse events/effects
Primary endpoint: Concentrations of protein bound uremic toxins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: GCF IL-26 level (ng/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: GCF IL-6 level (ng/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: GCF IL-10 level (ng/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Renal histopathology compatible with MGRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Responses to cardiac risk questions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Difference in Volume of Tophi Between Visits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in Volume of Tophi Between Readers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of confirmed venous thromboembolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Ricci-Gagnon score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Acetylcholine (ACh) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Dopamine (DA) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants With Change From Baseline in QTcF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ablation Outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Bulbar Conjunctival Hyperemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variation of the instantaneous NIPE index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hardiness (change over time)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Preference for dressing choice
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sensitivity and specificity of multi-analyte blood test vs ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Grade 2 or Higher Dysphagia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Virological response: Viral Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment-Emergent Abnormal High Prolactin at Any Time Post Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Participants With Treatment-Emergent Abnormal High Alanine Transaminase (ALT), High Aspartate Transaminase (AST), High Total Bilirubin at Any Time Post Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Having Normal Fasting Baseline Glucose Value With Treatment-Emergent High Fasting Glucose at Any Time Post Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in metabolic requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Habit strength
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Histological assessment of bony consolidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic performance for likelihood of appendicitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of injection site adverse reactions after vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of systematic adverse reactions after vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Percent Predicted Forced Vital Capacity (FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Schizophrenia Psychopathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse event collection
Endpoint domain: Adverse events/effects
Primary endpoint: Muscle Sympathetic Nerve Activity at Rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in EPC levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-injection reaction rates
Endpoint domain: Adverse events/effects
Primary endpoint: Polysomnography Sleep Quality
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: T1/2 gastric emptying of solids and liquids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Fasting whole gastric volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in International Restless Legs Syndrome rating scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnose accordance rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Patients Achieving a Favorable Outcome Defined as Modified Rankin Scale Score of 0 or 1
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pain during physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aorta dimensions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Language Quotient (LQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Median Steady-state Lapatinib Plasma Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Perioperative ischemic stroke rate
Endpoint domain: Mortality/survival
Primary endpoint: Perioperative death rate
Endpoint domain: Mortality/survival
Primary endpoint: Rate of transient neurological deficit (TND)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Torsade de pointes arrhythmia events
Endpoint domain: Adverse events/effects
Primary endpoint: expression of surface markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes